| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patient Reported Outcome Measures | 15 | 2023 | 799 | 1.530 |
Why?
|
| Quality of Life | 15 | 2020 | 4532 | 1.300 |
Why?
|
| Severity of Illness Index | 19 | 2021 | 4320 | 1.270 |
Why?
|
| Fatigue | 13 | 2021 | 1239 | 1.110 |
Why?
|
| Pain Measurement | 7 | 2020 | 953 | 1.000 |
Why?
|
| Activities of Daily Living | 3 | 2017 | 552 | 0.970 |
Why?
|
| Lung Neoplasms | 21 | 2020 | 11538 | 0.870 |
Why?
|
| Multiple Myeloma | 8 | 2021 | 2138 | 0.840 |
Why?
|
| Health Status | 6 | 2015 | 590 | 0.810 |
Why?
|
| Polymorphism, Genetic | 10 | 2007 | 1450 | 0.810 |
Why?
|
| Gynecologic Surgical Procedures | 7 | 2023 | 356 | 0.800 |
Why?
|
| Minocycline | 5 | 2021 | 182 | 0.800 |
Why?
|
| Pain | 9 | 2021 | 1658 | 0.760 |
Why?
|
| Thoracotomy | 3 | 2016 | 220 | 0.710 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2016 | 209 | 0.630 |
Why?
|
| Psychometrics | 6 | 2020 | 937 | 0.610 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2014 | 4549 | 0.580 |
Why?
|
| Inflammation Mediators | 4 | 2014 | 423 | 0.570 |
Why?
|
| Alopecia Areata | 2 | 2013 | 55 | 0.570 |
Why?
|
| Cancer Pain | 2 | 2019 | 312 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2020 | 5319 | 0.490 |
Why?
|
| Recovery of Function | 2 | 2016 | 703 | 0.460 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 600 | 0.460 |
Why?
|
| Middle Aged | 63 | 2021 | 86204 | 0.460 |
Why?
|
| Surveys and Questionnaires | 10 | 2020 | 5687 | 0.450 |
Why?
|
| Pain, Postoperative | 6 | 2020 | 610 | 0.430 |
Why?
|
| Arthralgia | 1 | 2013 | 89 | 0.430 |
Why?
|
| Aged | 54 | 2020 | 70117 | 0.420 |
Why?
|
| Analgesics | 2 | 2017 | 390 | 0.420 |
Why?
|
| Health Status Indicators | 2 | 2015 | 224 | 0.420 |
Why?
|
| Inflammation | 4 | 2014 | 2522 | 0.400 |
Why?
|
| Cost of Illness | 5 | 2016 | 498 | 0.390 |
Why?
|
| Exercise | 1 | 2017 | 1183 | 0.350 |
Why?
|
| Female | 61 | 2023 | 141928 | 0.350 |
Why?
|
| Mental Recall | 1 | 2010 | 171 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 8 | 2019 | 3976 | 0.340 |
Why?
|
| Ferredoxin-NADP Reductase | 2 | 2005 | 14 | 0.340 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2005 | 24 | 0.340 |
Why?
|
| Models, Theoretical | 1 | 2013 | 785 | 0.330 |
Why?
|
| Triazoles | 1 | 2013 | 617 | 0.330 |
Why?
|
| Nitriles | 1 | 2013 | 906 | 0.320 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2005 | 102 | 0.320 |
Why?
|
| Self Report | 5 | 2016 | 756 | 0.320 |
Why?
|
| Thymidylate Synthase | 2 | 2004 | 53 | 0.320 |
Why?
|
| Male | 54 | 2020 | 123000 | 0.320 |
Why?
|
| Pain Management | 2 | 2019 | 668 | 0.310 |
Why?
|
| Symptom Assessment | 5 | 2021 | 267 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 840 | 0.310 |
Why?
|
| Humans | 75 | 2023 | 261506 | 0.300 |
Why?
|
| Prospective Studies | 14 | 2023 | 12873 | 0.300 |
Why?
|
| Stress, Psychological | 2 | 2013 | 1000 | 0.300 |
Why?
|
| Registries | 2 | 2013 | 2170 | 0.290 |
Why?
|
| Longitudinal Studies | 9 | 2021 | 1945 | 0.280 |
Why?
|
| Aged, 80 and over | 23 | 2020 | 29902 | 0.270 |
Why?
|
| Adult | 37 | 2020 | 77950 | 0.270 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 2 | 2007 | 96 | 0.260 |
Why?
|
| Genotype | 10 | 2014 | 4109 | 0.250 |
Why?
|
| Chemoradiotherapy | 3 | 2019 | 1946 | 0.250 |
Why?
|
| Genital Neoplasms, Female | 3 | 2021 | 735 | 0.250 |
Why?
|
| Risk Factors | 21 | 2018 | 17523 | 0.250 |
Why?
|
| Neoplasms | 6 | 2019 | 15193 | 0.240 |
Why?
|
| Postoperative Complications | 6 | 2023 | 5542 | 0.240 |
Why?
|
| Interleukin-6 | 4 | 2014 | 1038 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2010 | 5539 | 0.240 |
Why?
|
| Patient Discharge | 2 | 2023 | 661 | 0.230 |
Why?
|
| Insecticides | 1 | 2003 | 49 | 0.230 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 101 | 0.230 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 4971 | 0.220 |
Why?
|
| Sleep Wake Disorders | 5 | 2019 | 348 | 0.220 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 6009 | 0.210 |
Why?
|
| Myasthenia Gravis | 1 | 2003 | 99 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 573 | 0.210 |
Why?
|
| Perioperative Care | 3 | 2021 | 451 | 0.210 |
Why?
|
| Hepatectomy | 2 | 2019 | 1011 | 0.210 |
Why?
|
| Case-Control Studies | 13 | 2007 | 6100 | 0.200 |
Why?
|
| DNA Helicases | 1 | 2004 | 434 | 0.200 |
Why?
|
| Postoperative Period | 3 | 2021 | 665 | 0.200 |
Why?
|
| Bupivacaine | 1 | 2020 | 68 | 0.180 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 860 | 0.180 |
Why?
|
| DNA Repair | 2 | 2007 | 1872 | 0.180 |
Why?
|
| DNA Damage | 2 | 2007 | 1954 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 1371 | 0.180 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 163 | 0.170 |
Why?
|
| Radiodermatitis | 1 | 2019 | 75 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 482 | 0.170 |
Why?
|
| Area Under Curve | 2 | 2019 | 700 | 0.170 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 1105 | 0.160 |
Why?
|
| Sex Factors | 4 | 2016 | 2139 | 0.160 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2017 | 30 | 0.160 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 73 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2019 | 110 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2019 | 1546 | 0.150 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 167 | 0.150 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2017 | 59 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.150 |
Why?
|
| Glycine Hydroxymethyltransferase | 2 | 2007 | 9 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2992 | 0.140 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 4314 | 0.140 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 245 | 0.140 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 102 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 3203 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 14889 | 0.140 |
Why?
|
| Paresthesia | 1 | 2016 | 33 | 0.140 |
Why?
|
| Organoplatinum Compounds | 2 | 2016 | 702 | 0.140 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 301 | 0.140 |
Why?
|
| Pyridazines | 1 | 2018 | 293 | 0.140 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.140 |
Why?
|
| Touch | 1 | 2016 | 71 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 521 | 0.130 |
Why?
|
| Proteins | 1 | 2004 | 1963 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2019 | 393 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2017 | 739 | 0.130 |
Why?
|
| Proton Therapy | 2 | 2016 | 1577 | 0.130 |
Why?
|
| 3' Untranslated Regions | 3 | 2005 | 343 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2005 | 5437 | 0.130 |
Why?
|
| Wound Healing | 1 | 2020 | 815 | 0.130 |
Why?
|
| Prevalence | 3 | 2017 | 3260 | 0.130 |
Why?
|
| Dasatinib | 1 | 2018 | 862 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2020 | 851 | 0.130 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 475 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2012 | 77 | 0.130 |
Why?
|
| Young Adult | 8 | 2020 | 21445 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 15694 | 0.130 |
Why?
|
| Adolescent | 9 | 2019 | 31252 | 0.120 |
Why?
|
| Interleukin-10 | 2 | 2014 | 478 | 0.120 |
Why?
|
| Carcinogens | 2 | 2007 | 384 | 0.120 |
Why?
|
| Double-Blind Method | 4 | 2021 | 2588 | 0.120 |
Why?
|
| Cystectomy | 1 | 2018 | 623 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 406 | 0.120 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2018 | 505 | 0.120 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2004 | 239 | 0.120 |
Why?
|
| Transplantation, Autologous | 2 | 2015 | 1914 | 0.120 |
Why?
|
| Deglutition Disorders | 2 | 2019 | 447 | 0.120 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 690 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 300 | 0.110 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 3578 | 0.110 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 14289 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2019 | 1529 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 129 | 0.110 |
Why?
|
| Time Factors | 6 | 2016 | 12926 | 0.110 |
Why?
|
| Imidazoles | 1 | 2018 | 999 | 0.110 |
Why?
|
| DNA Primers | 2 | 2005 | 1399 | 0.110 |
Why?
|
| Smoking | 8 | 2007 | 2440 | 0.110 |
Why?
|
| Photons | 1 | 2016 | 507 | 0.110 |
Why?
|
| Cause of Death | 2 | 2007 | 752 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2018 | 650 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 4298 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 1538 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2011 | 31 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2020 | 32848 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 4638 | 0.100 |
Why?
|
| Pain Perception | 1 | 2010 | 13 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 4821 | 0.100 |
Why?
|
| China | 5 | 2007 | 606 | 0.100 |
Why?
|
| Cohort Studies | 6 | 2015 | 9244 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.090 |
Why?
|
| Reminder Systems | 1 | 2011 | 83 | 0.090 |
Why?
|
| United States | 3 | 2017 | 15433 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2004 | 5270 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2015 | 831 | 0.090 |
Why?
|
| Proof of Concept Study | 2 | 2019 | 53 | 0.090 |
Why?
|
| Family | 1 | 2013 | 736 | 0.090 |
Why?
|
| Cytokines | 4 | 2014 | 2809 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 200 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 2218 | 0.090 |
Why?
|
| Perioperative Period | 2 | 2021 | 155 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 1910 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 402 | 0.080 |
Why?
|
| Incidence | 3 | 2019 | 5673 | 0.080 |
Why?
|
| Esophageal Neoplasms | 2 | 2012 | 3168 | 0.080 |
Why?
|
| Base Sequence | 2 | 2005 | 4917 | 0.080 |
Why?
|
| Self-Assessment | 1 | 2008 | 96 | 0.080 |
Why?
|
| Texas | 6 | 2019 | 6311 | 0.080 |
Why?
|
| Men's Health | 1 | 2007 | 19 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2015 | 6550 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 252 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 443 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 8865 | 0.070 |
Why?
|
| Alkylating Agents | 1 | 2007 | 78 | 0.070 |
Why?
|
| Dyspnea | 3 | 2019 | 416 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2013 | 1171 | 0.070 |
Why?
|
| Cytosol | 1 | 2007 | 238 | 0.070 |
Why?
|
| Smoking Cessation | 2 | 2002 | 712 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 2238 | 0.070 |
Why?
|
| Haplotypes | 2 | 2005 | 856 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3518 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2007 | 430 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 2341 | 0.070 |
Why?
|
| Survivors | 1 | 2011 | 1031 | 0.070 |
Why?
|
| Telemedicine | 1 | 2011 | 471 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 2104 | 0.060 |
Why?
|
| 5' Untranslated Regions | 1 | 2004 | 93 | 0.060 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 69 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.060 |
Why?
|
| DNA Glycosylases | 1 | 2004 | 93 | 0.060 |
Why?
|
| Length of Stay | 2 | 2023 | 1900 | 0.060 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 13658 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 1053 | 0.060 |
Why?
|
| Cholinesterases | 1 | 2003 | 9 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2003 | 16 | 0.060 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.060 |
Why?
|
| Genes, bcl-1 | 1 | 2003 | 24 | 0.060 |
Why?
|
| DNA Adducts | 1 | 2004 | 210 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4757 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2019 | 1987 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2008 | 1819 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 21713 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 5061 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 359 | 0.050 |
Why?
|
| Energy Intake | 1 | 2004 | 515 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2007 | 1234 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2013 | 6869 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3719 | 0.050 |
Why?
|
| Homozygote | 1 | 2003 | 717 | 0.050 |
Why?
|
| Military Personnel | 1 | 2003 | 225 | 0.050 |
Why?
|
| Point Mutation | 1 | 2003 | 769 | 0.050 |
Why?
|
| Mortality | 1 | 2002 | 343 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2005 | 2316 | 0.050 |
Why?
|
| Recurrence | 1 | 2008 | 4758 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 1351 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 409 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2020 | 37905 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 259 | 0.040 |
Why?
|
| Stroke | 2 | 2007 | 1144 | 0.040 |
Why?
|
| Gene Frequency | 3 | 2007 | 1163 | 0.040 |
Why?
|
| Veterans | 2 | 2007 | 1641 | 0.040 |
Why?
|
| Liposomes | 1 | 2020 | 684 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 500 | 0.040 |
Why?
|
| Diet | 1 | 2005 | 1440 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4892 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2045 | 0.030 |
Why?
|
| Coronary Disease | 3 | 2007 | 764 | 0.030 |
Why?
|
| Salpingectomy | 1 | 2015 | 43 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2015 | 2803 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2007 | 497 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2015 | 330 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 543 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 980 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2019 | 786 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 684 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2005 | 551 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 1085 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1014 | 0.020 |
Why?
|
| Liver | 1 | 2021 | 2961 | 0.020 |
Why?
|
| Feeding and Eating Disorders | 1 | 2012 | 97 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2015 | 611 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2011 | 53 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 669 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2012 | 2203 | 0.020 |
Why?
|
| Telephone | 1 | 2011 | 163 | 0.020 |
Why?
|
| Alleles | 2 | 2007 | 2437 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 3472 | 0.020 |
Why?
|
| Survival Rate | 2 | 2019 | 12221 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2009 | 2086 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 2352 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 726 | 0.020 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 7789 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 1225 | 0.020 |
Why?
|
| Alkylation | 1 | 2007 | 29 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2007 | 71 | 0.020 |
Why?
|
| Sulfuric Acid Esters | 1 | 2007 | 10 | 0.020 |
Why?
|
| Logistic Models | 2 | 2005 | 3441 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2007 | 50 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5112 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 1021 | 0.020 |
Why?
|
| Biological Assay | 1 | 2007 | 177 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 4975 | 0.020 |
Why?
|
| Plasmids | 1 | 2007 | 837 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Codon | 1 | 2005 | 241 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 1824 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1323 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 528 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 756 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 176 | 0.010 |
Why?
|
| Retirement | 1 | 2002 | 22 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 2843 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 1688 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1544 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 3254 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 235 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 1972 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 4988 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 5637 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1467 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2002 | 717 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2002 | 1011 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 1503 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 6682 | 0.010 |
Why?
|
| Child | 1 | 2005 | 29154 | 0.000 |
Why?
|